Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
hematoporphyrin + bacillus calmette-guérin
- Development stage
- Unknown
- Lead developer
- Cancer Hospital
- Modality
- Small Molecules, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Vaccines & Immunotherapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Intravesical
01
Overview
This combination therapy involves the sequential or concurrent use of photodynamic therapy (PDT) with hematoporphyrin (or its derivative, HpD) and immunotherapy with Bacillus Calmette-Guérin (BCG). It is primarily investigated for the treatment of non-muscle invasive bladder cancer (NMIBC). Hematoporphyrin acts as a photosensitizing agent that, upon activation by specific wavelengths of light, generates reactive oxygen species (ROS) to induce direct tumor cell death and vascular damage. BCG is a live-attenuated strain of Mycobacterium bovis that, when instilled intravesically, induces a robust local inflammatory and immune response in the bladder wall, leading to the destruction of residual cancer cells. The combination aims to leverage the immediate cytotoxic effects of PDT with the sustained immunological surveillance provided by BCG to enhance therapeutic efficacy and reduce recurrence rates. Research on this combination has been notably conducted by institutions such as the Cancer Hospital of the Chinese Academy of Medical Sciences and Shenzhen Hospital.
- Other names
- HpD + BCGPhotodynamic therapy + BCGHematoporphyrin derivative + BCG
02
Targets
DNA
Beyond the preview
Go deeper on hematoporphyrin + bacillus calmette-guérin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on hematoporphyrin + bacillus calmette-guérin.